We are now regaining the exclusive, global rights to develop and commercialize ADC-1013 and at the same time receive enough ADC-1013 substance to, with or without a new partner, bring ADC-1013 into Phase II clinical trials next year. In total, we now have three projects in clinical development, and soon another one where the first patient in Phase I will be dosed.
Engaging Theradex is a key step towards starting our clinical phase I study with ATOR-1015 later this year. We have worked previously with Theradex on the ADC-1013 clinical phase I trial and, based on their robust delivery and extensive expertise in clinical oncology research, we are confident in their ability to assist us in executing high-quality studies and we look forward to continuing our successful collaboration.
With three preclinical projects approaching clinical development and our business model to out-license projects after proof-of-concept in cancer patients, we are very pleased to make this important appointment to the management team. We look forward to welcoming Anu to Alligator. He brings extensive international experience in drug licensing and collaboration, complementing the growing team at Alligator.
We are pleased that our collaboration with Janssen is continuing to progress according to plan. The upcoming combination is a very important step in the continued clinical development. Synergy between ADC-1013 and PD-1 blocking antibodies is supported by pre-clinical data. If this translates to the clinic, it could create new treatment opportunities for many cancer patients.
We are very excited about the continued progress and promising early data of ADC-1013. The data indicate that it is well tolerated at clinically relevant doses. There is clear evidence supporting activation of CD40 receptors, which together with the clinical observations gives us increased confidence for the continued clinical development of ADC-1013.
I am very enthusiastic about the extended collaboration with Alligator. Its 4-1BB drug candidates provide great new treatment opportunities within immuno-oncology. The fact that 4-1BB is upregulated on tumor-specific T cells, together with its capacity to promote survival, expansion and functional activity of several immune cells involved in tumor eradication, makes 4-1BB a uniquely appealing target for immunotherapy of cancer.
We are very fortunate to have Professor Melero as a research collaborator. He is a world leading expert in the field of 4-1BB and immunotherapy and his scientific guidance will be extremely valuable both for our pipeline projects, and to help fulfill our ambition to deliver first and best-in-class products to patients.
With CMC and IND enabling activities underway, our partnership with Aptevo is moving ahead rapidly. Having worked collaboratively to design and engineer ALG.APV-527, we are pleased to now announce its advancement into preclinical development. This bispecific antibody brings tumor directed immunotherapy to the next level. By making the immune activation dependent on binding to a tumor antigen we have created a candidate drug with potential for improved efficacy and fewer side effects.